Rimini Street (RMNI) Competitors

NeoGenomics (NASDAQ:NEO) and Rimini Street (NASDAQ:RMNI) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, profitability, community ranking, institutional ownership, media sentiment, analyst recommendations, valuation and risk.

Does the media refer more to NEO or RMNI?

In the previous week, NeoGenomics had 3 more articles in the media than Rimini Street. MarketBeat recorded 6 mentions for NeoGenomics and 3 mentions for Rimini Street. Rimini Street's average media sentiment score of 1.11 beat NeoGenomics' score of 0.63 indicating that Rimini Street is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NeoGenomics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Rimini Street	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Does the MarketBeat Community believe in NEO or RMNI?

NeoGenomics received 352 more outperform votes than Rimini Street when rated by MarketBeat users. Likewise, 70.81% of users gave NeoGenomics an outperform vote while only 63.52% of users gave Rimini Street an outperform vote.

Company	Underperform	Outperform
NeoGenomics	Outperform Votes 507 70.81%	Underperform Votes 209 29.19%
Rimini Street	Outperform Votes 155 63.52%	Underperform Votes 89 36.48%

Do insiders & institutionals have more ownership in NEO or RMNI?

98.5% of NeoGenomics shares are owned by institutional investors. Comparatively, 73.8% of Rimini Street shares are owned by institutional investors. 1.3% of NeoGenomics shares are owned by insiders. Comparatively, 41.0% of Rimini Street shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Do analysts rate NEO or RMNI?

NeoGenomics currently has a consensus price target of $19.60, indicating a potential upside of 106.32%. Rimini Street has a consensus price target of $5.25, indicating a potential upside of 61.04%. Given NeoGenomics' higher probable upside, research analysts clearly believe NeoGenomics is more favorable than Rimini Street.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeoGenomics	0 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.80
Rimini Street	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has more risk and volatility, NEO or RMNI?

NeoGenomics has a beta of 1.41, meaning that its share price is 41% more volatile than the S&P 500. Comparatively, Rimini Street has a beta of 1.31, meaning that its share price is 31% more volatile than the S&P 500.

Is NEO or RMNI more profitable?

Rimini Street has a net margin of -7.87% compared to NeoGenomics' net margin of -11.92%. NeoGenomics' return on equity of -2.10% beat Rimini Street's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeoGenomics	-11.92%	-2.10%	-1.17%
Rimini Street	-7.87%	-83.26%	10.79%

Which has preferable valuation and earnings, NEO or RMNI?

Rimini Street has lower revenue, but higher earnings than NeoGenomics. NeoGenomics is trading at a lower price-to-earnings ratio than Rimini Street, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeoGenomics	$660.57M	1.85	-$87.97M	-$0.62	-15.32
Rimini Street	$428.75M	0.69	$26.06M	-$0.40	-8.15

Summary

NeoGenomics beats Rimini Street on 10 of the 18 factors compared between the two stocks.